BioPharmSignal logoBioPharmSignal

Biotech News

Celldex to Present at Upcoming Investor Conference

Celldex Therapeutics (CLDX)Celldex TherapeuticsConference / presentation

Celldex (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the upcoming Cantor Global Healthcare Conference on September 10, 2026 at 8:00am ET.

The webcast of the presentation will be available on the “ Events and Presentations ” page of the “Investors” section of the Celldex Website. Replays will be available for 90 days following the event.

About Celldex Celldex is pioneering new horizons in immunology to deliver life-changing therapies. We are relentless in our pursuit of novel antibody-based treatments that engage the human immune system and directly affect critical pathways to improve the lives of patients with allergic, inflammatory and autoimmune disorders. Visit www.celldex.com .

Company Contacts Sarah Cavanaugh Senior Vice President, Corporate Affairs & Administration (508) 864-8337 [email protected]

Elizabeth Higgins Executive Director, Investor Relations & Corporate Communications (857) 404-2088 [email protected]

Related news

XGNExagen2026-07-28 13:00 EST

Exagen Inc. to Participate in Upcoming Investor Conference

INMBINmune Bio2026-09-09 12:00 EST

INmune Bio to Present at the H.C. Wainwright Global Investment Conference

KNSAKiniksa2026-09-04 20:01 EST

Kiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare Conference

REGNRegeneron Pharmaceuticals2026-08-19 20:05 EST

Regeneron Announces Investor Conference Presentations

KNSAKiniksa2026-08-07 20:01 EST

Kiniksa Pharmaceuticals to Present at Canaccord Genuity 46th Annual Growth Conference

XFORX4 Pharmaceuticals2026-09-09 11:00 EST

X4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare Conference

ACRSAclaris Therapeutics2026-09-03 12:00 EST

Aclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

ANABAnaptysBio, Inc.2026-09-01 20:15 EST

Anaptys Announces Participation at the H.C. Wainwright 28th Annual Global Investment Conference

ZURAZura Bio2026-08-31 20:30 EST

Zura Bio to Participate in the Cantor Global Healthcare Conference

BMYBMYBristol-Myers Squibb Company2026-08-29 15:00 EST

Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026

View all latest news

Celldex Therapeutics

Mast Cell-Targeted Immunology Company Celldex Therapeutics is developing barzolvolimab, a KIT-targeting antibody for mast cell-driven diseases. Because KIT signaling is central to mast cell survival and function, the therapy is intended to provide deeper disease modification than symptom-focused treatment alone. Barzolvolimab in...

Recent company news

CLDXCelldex Therapeutics2026-09-08 20:01 EST

Celldex to Present at Upcoming Investor Conference

CLDXCelldex Therapeutics2026-08-06 20:01 EST

Celldex Reports Second Quarter Financial Results and Provides Corporate Update

CLDXCelldex Therapeutics2026-07-21 20:01 EST

Celldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis

CLDXCelldex Therapeutics2026-07-15 20:01 EST

Celldex Announces Planned Transition of Chief Financial Officer

CLDXCelldex Therapeutics2026-06-14 14:21 EST

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting

Stock data

Close
38.98 USD
Market cap
2.27B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States